Vision Institute

Built in the heart of the Quinze-Vingts National Eye Hospital Paris, France, the Vision Institute (French: Institut de la Vision) is one of the most important research centers (Inserm / UPMC / CNRS) in Europe on eye diseases.[1]

Vision Institute (Institut de la Vision)
Founder(s)Jose-Alain Sahel
Established2008
FocusEye diseases
PresidentJose-Alain Sahel
Location,
Address17 rue Moreau 75012 Paris
Websitehttp://www.institut-vision.org/

The Institute's goal is to discover, develop and test treatments and technological innovations in the area ophthalmology and to improve the autonomy and the quality of life of patients.[2]

Research areas

Basic research

Vision Institute employs more than 250 scientists (Inserm - UPMC - CNRS) specialized in vision disorders.

There are 4 research departments:[3]

  • Developmental biology: analysis of the development of the visual system, connectics, stems cells and regenerative approaches
  • Visual information data processing: understanding and evaluation of the visual information data processing by the retina and the brain, neurotransmission pharmaco-toxicology
  • Genetics: understanding of the genetic mechanisms associated with ophthalmological disorders, identification of the genes and proteins providing protection against neuronal stress
  • Therapeutics: conception and evaluation of innovative treatments - cell therapy for cornea, pharmaco-toxicology of the ocular surface and glaucoma, gene therapy for neuropathies, modeling of retinal degeneration and vascular disorders

Clinical research

The Ophthalmological Clinical Investigation Centre of the Quinze-Vingts National Eye Hospital opened in 2004.

The Clinical Investigation Centre covers all eye diseases but is specialised in exploration of retinal pathologies (macular degeneration, hereditary retinal degenerations, diabetic retinopathies, retinal vascular pathologies) and technological innovations.

Research in the quality of life

The Vision Institute runs a StreetLab Platform Project. The StreetLab platform enables researchers to design and develop innovative technology solutions for the visually impaired while being able to evaluate the therapeutic benefit of this research directly with the people involved.[2]

Foundation Voir et Entendre

The Foundation Voir et Entendre was created in May 2007 by Prof. Christine Petit (Institut Pasteur, Collège de France) and Prof. José-Alain Sahel.

The Foundation's objective is to coordinate and to finance research programs on ocular and auditory diseases. Its mission is to stimulate the collaboration between fundamental, clinical and industrial research, so as to accelerate therapeutic innovation for the benefit of the patients.[4]

Industrial collaborations

Five major companies have settled in the Institute to develop research projects in the field of vision: Essilor, Sanofi Fovea, Thea, Horus Pharma and Iris Pharma.[5]

gollark: They get sent in as incident reports.
gollark: I actually monitor complaints about potatOS in the SC chat.
gollark: <@!426660245738356738> It'll probably still be possible to get around that. As I have said: full sandboxing is very hard and people still often discover potatOS exploits.
gollark: It blocks BlahOS, the highly dangerous ██████ Siri, Webicity, that sort of thing.
gollark: PotatOS actually incorporates its own bad-code scanner.

References

  1. "Institut de la Vision Paris". www.vision-research.eu. European Vision Institute. Retrieved 4 June 2014.
  2. "The Vision Institute Inaugurates StreetLab Platform". www.upmc.fr. UPMC, Sorbonne Universités. Retrieved 10 June 2014.
  3. "Teams". www.institut-vision.org. Archived from the original on 17 November 2011.
  4. HendiCapZero. "fondation voir et entendre". www.handicapzero.org. Retrieved 10 June 2014.
  5. "The Institut de la Vision and Iris Pharma Join Forces to Strengthen the Bond Between the Private and Public Sectors, and Between Industry and Academic Research". www.prnewswire.co.uk. PR Newswire. Archived from the original on 4 March 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.